{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:25:06Z","timestamp":1793496306845,"version":"4.5.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We conducted a systematic review and meta-analysis to examine outcomes of patients with endometrial intraepithelial neoplasia treated with oral progestins or a levonorgestrel-releasing intrauterine device (IUD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic review across 5 databases to examine outcomes of progestational treatment (oral progestins or levonorgestrel-releasing IUD) for patients with endometrial intraepithelial neoplasia. The primary outcome was the best complete response rate within 12 months of primary progestational treatment. Sensitivity analyses were performed by removing studies with extreme effect sizes. Secondary outcomes included the pooled pregnancy rate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 21 eligible studies, including 824 premenopausal patients with endometrial intraepithelial neoplasia, for our meta-analysis. Among these, 459 patients received oral progestin, and 365 patients received levonorgestrel-releasing IUD as a primary progestational treatment. The pooled best complete response proportion within 12\u2009months was 82% (95% confidence interval [CI] = 69% to 91%) following oral progestin treatment and 95% (95% CI = 81% to 99%) following levonorgestrel-releasing IUD treatment. After removing outlier studies, the pooled proportion was 86% (95% CI = 75% to 92%) for the oral progestin group and 96% (95% CI = 91% to 99%) for the levonorgestrel-releasing IUD group, with reduced heterogeneity. The pooled pregnancy rate was 50% (95% CI = 35% to 65%) after oral progestin and 35% (95% CI = 23% to 49%) after levonorgestrel-releasing IUD treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This meta-analysis provides data on the effectiveness of oral progestins and levonorgestrel-releasing IUD treatment within 12\u2009months of treatment among premenopausal patients with endometrial intraepithelial neoplasia. Although based on small numbers, the rate of pregnancy after treatment is modest. These data may be beneficial for selecting progestational therapies that allow fertility preservation for patients with endometrial intraepithelial neoplasia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djae023","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T14:31:52Z","timestamp":1706884312000},"page":"653-664","source":"Crossref","is-referenced-by-count":16,"title":["Levonorgestrel-releasing intrauterine device therapy vs oral progestin treatment for reproductive-aged patients with endometrial intraepithelial neoplasia: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"116","author":[{"given":"Yukio","family":"Suzuki","sequence":"first","affiliation":[{"name":"Columbia University College of Physicians and Surgeons , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Ferris","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons , New York, NY,","place":["USA"]},{"name":"Joseph L. Mailman School of Public Health, Columbia University , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Dioun","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons , New York, NY,","place":["USA"]},{"name":"Herbert Irving Comprehensive Cancer Center , New York, NY,","place":["USA"]},{"name":"New York Presbyterian Hospital , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Usseglio","sequence":"additional","affiliation":[{"name":"Augustus C. Long Health Sciences Library, Columbia University Irving Medical Center , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[{"name":"University of Southern California , Los Angeles, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons , New York, NY,","place":["USA"]},{"name":"Joseph L. Mailman School of Public Health, Columbia University , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L","family":"Hershman","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons , New York, NY,","place":["USA"]},{"name":"Joseph L. Mailman School of Public Health, Columbia University , New York, NY,","place":["USA"]},{"name":"Herbert Irving Comprehensive Cancer Center , New York, NY,","place":["USA"]},{"name":"New York Presbyterian Hospital , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6390-825X","authenticated-orcid":false,"given":"Jason D","family":"Wright","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons , New York, NY,","place":["USA"]},{"name":"Herbert Irving Comprehensive Cancer Center , New York, NY,","place":["USA"]},{"name":"New York Presbyterian Hospital , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024102109252544800_djae023-B1","year":"2023"},{"issue":"6","key":"2024102109252544800_djae023-B2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ajog.2020.12.1213","article-title":"Ovarian conservation for young women with early-stage, low-grade endometrial cancer: a 2-step schema","volume":"224","author":"Matsuo","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2024102109252544800_djae023-B3","first-page":"979","article-title":"Systemic progestins and progestin-releasing intrauterine device therapy for premenopausal patients with endometrial intraepithelial neoplasia","volume":"141","author":"Suzuki","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"20","key":"2024102109252544800_djae023-B4","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: Have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2024102109252544800_djae023-B5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.2009.24.1315","article-title":"Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia","volume":"28","author":"Lacey","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024102109252544800_djae023-B6","first-page":"1061","article-title":"Endometrial Hyperplasia","volume":"140","author":"Ring","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2024102109252544800_djae023-B7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/AOG.0000000000005297","article-title":"Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG clinical consensus no. 5","volume":"142","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2024102109252544800_djae023-B8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"2024102109252544800_djae023-B9","article-title":"Oral and intrauterine progestogens for atypical endometrial hyperplasia","volume":"2018","author":"Luo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2024102109252544800_djae023-B10","first-page":"CD012658","article-title":"Levonorgestrel-releasing intrauterine system for endometrial hyperplasia","volume":"9","author":"Mittermeier","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2024102109252544800_djae023-B11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1471-0528.12499","article-title":"Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial","volume":"121","author":"\u00d8rbo","year":"2014","journal-title":"BJOG"},{"issue":"37","key":"2024102109252544800_djae023-B12","doi-asserted-by":"crossref","first-page":"e8034","DOI":"10.1097\/MD.0000000000008034","article-title":"Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review","volume":"96","author":"Wei","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"2024102109252544800_djae023-B13","doi-asserted-by":"crossref","first-page":"102432","DOI":"10.1016\/j.jogoh.2022.102432","article-title":"Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: a systemic review and meta-analysis","volume":"51","author":"Elassall","year":"2022","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"3","key":"2024102109252544800_djae023-B14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.fertnstert.2013.11.028","article-title":"Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis","volume":"101","author":"Koskas","year":"2014","journal-title":"Fertil Steril"},{"issue":"1","key":"2024102109252544800_djae023-B15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ygyno.2011.11.043","article-title":"Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature","volume":"125","author":"Baker","year":"2012","journal-title":"Gynecol Oncol"},{"key":"2024102109252544800_djae023-B16","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160:n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024102109252544800_djae023-B17"},{"key":"2024102109252544800_djae023-B18","author":"Aromataris","year":"2020"},{"key":"2024102109252544800_djae023-B19","doi-asserted-by":"crossref","DOI":"10.1201\/9781003107347","volume-title":"Doing Meta-Analysis with R: A Hands-On Guide","author":"Harrer","year":"2021","edition":"1st ed"},{"issue":"2","key":"2024102109252544800_djae023-B20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"17","key":"2024102109252544800_djae023-B21","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med"},{"issue":"7109","key":"2024102109252544800_djae023-B22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"6","key":"2024102109252544800_djae023-B23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA"},{"key":"2024102109252544800_djae023-B24","doi-asserted-by":"crossref","first-page":"812346","DOI":"10.3389\/fonc.2022.812346","article-title":"Fertility-sparing treatment for endometrial cancer or atypical endometrial hyperplasia patients with obesity","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"2024102109252544800_djae023-B25","doi-asserted-by":"crossref","first-page":"11795549221110522","DOI":"10.1177\/11795549221110522","article-title":"Hysteroscopic curettage followed by megestrol acetate plus metformin as a fertility-sparing treatment for women with atypical endometrial hyperplasia or well-differentiated endometrioid endometrial carcinoma","volume":"16","author":"Jing","year":"2022","journal-title":"Clin Med Insights Oncol"},{"issue":"3","key":"2024102109252544800_djae023-B26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/jrpp.JRPP_20_128","article-title":"Effectiveness of megestrol for the treatment of patients with atypical endometrial hyperplasia or endometrial endometrioid adenocarcinoma (Stage IA, well differentiated)","volume":"10","author":"Akhavan","year":"2021","journal-title":"J Res Pharm Pract"},{"issue":"5","key":"2024102109252544800_djae023-B27","first-page":"5412","article-title":"LNG-IUS combined with progesterone ameliorates endometrial thickness and pregnancy outcomes of patients with early-stage endometrial cancer or atypical hyperplasia","volume":"13","author":"Fang","year":"2021","journal-title":"Am J Transl Res"},{"issue":"1","key":"2024102109252544800_djae023-B28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2021.01.001","article-title":"Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer","volume":"161","author":"Novikova","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2024102109252544800_djae023-B29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/jayao.2020.0100","article-title":"Clinical predictive factors of response to treatment in patients undergoing conservative management of atypical endometrial hyperplasia and early endometrial cancer","volume":"10","author":"Raffone","year":"2021","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"12","key":"2024102109252544800_djae023-B30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123571","article-title":"Fertility sparing treatment of endometrial cancer with and without initial infiltration of myometrium: a single center experience","volume":"12","author":"Casadio","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2024102109252544800_djae023-B31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jmig.2018.07.001","article-title":"Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retrospective study","volume":"26","author":"Giampaolino","year":"2019","journal-title":"J Minim Invasive Gynecol"},{"issue":"1","key":"2024102109252544800_djae023-B32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/jog.13473","article-title":"Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer","volume":"44","author":"Tamauchi","year":"2018","journal-title":"J Obstetr Gynaecol Res"},{"issue":"1","key":"2024102109252544800_djae023-B33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijgo.2015.06.046","article-title":"Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer","volume":"132","author":"Chen","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"2024102109252544800_djae023-B34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/annonc\/mdv539","article-title":"Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"27","author":"Mitsuhashi","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"2024102109252544800_djae023-B35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00404-014-3417-z","article-title":"Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature","volume":"291","author":"Ohyagi-Hara","year":"2015","journal-title":"Arch Gynecol Obstet"},{"issue":"10","key":"2024102109252544800_djae023-B36","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/1933719114522517","article-title":"Complex atypical hyperplasia of the endometrium: Differences in outcome following conservative management of pre- and postmenopausal women","volume":"21","author":"Brownfoot","year":"2014","journal-title":"Reprod Sci"},{"issue":"3","key":"2024102109252544800_djae023-B37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3802\/jgo.2014.25.3.214","article-title":"Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia","volume":"25","author":"Shan","year":"2014","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"2024102109252544800_djae023-B38","first-page":"1037","article-title":"Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility","volume":"32","author":"Koskas","year":"2012","journal-title":"Anticancer Res"},{"issue":"7","key":"2024102109252544800_djae023-B39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/09513590.2011.649813","article-title":"The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study","volume":"28","author":"Pashov","year":"2012","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"2024102109252544800_djae023-B40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/annonc\/mdq463","article-title":"Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women","volume":"22","author":"Minig","year":"2011","journal-title":"Ann Oncol"},{"issue":"6","key":"2024102109252544800_djae023-B41","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.fertnstert.2009.06.013","article-title":"Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium","volume":"92","author":"Yu","year":"2009","journal-title":"Fertil Steril"},{"issue":"19","key":"2024102109252544800_djae023-B42","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","article-title":"Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women","volume":"25","author":"Ushijima","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024102109252544800_djae023-B43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0304-3835(01)00462-1","article-title":"Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome","volume":"167","author":"Kaku","year":"2001","journal-title":"Cancer Lett"},{"issue":"7","key":"2024102109252544800_djae023-B44","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1471-0528.16108","article-title":"Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial","volume":"127","author":"Yang","year":"2020","journal-title":"BJOG"},{"issue":"1","key":"2024102109252544800_djae023-B45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12874-017-0391-8","article-title":"Clarifying the distinction between case series and cohort studies in systematic reviews of comparative studies: potential impact on body of evidence and workload","volume":"17","author":"Mathes","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2024102109252544800_djae023-B46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/B978-0-323-44732-4.00017-0","volume-title":"Diagnostic Gynecologic and Obstetric Pathology","author":"Mutter","year":"2018","edition":"3rd ed."},{"issue":"6","key":"2024102109252544800_djae023-B47","doi-asserted-by":"crossref","first-page":"547.e1","DOI":"10.1016\/j.ajog.2010.07.037","article-title":"Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis","volume":"203","author":"Gallos","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"2024102109252544800_djae023-B48","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/PAS.0b013e31802d68ce","article-title":"Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins","volume":"31","author":"Wheeler","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2024102109252544800_djae023-B49","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0002-9378(89)90103-8","article-title":"The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia","volume":"160","author":"Ferenczy","year":"1989","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2024102109252544800_djae023-B50","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1245\/s10434-016-5699-9","article-title":"Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: a meta-analysis","volume":"24","author":"Yuk","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2024102109252544800_djae023-B51","first-page":"686","article-title":"Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia","volume":"19","author":"Behnamfar","year":"2014","journal-title":"J Res Med Sci"},{"issue":"9","key":"2024102109252544800_djae023-B52","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/1471-0528.13763","article-title":"Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens","volume":"123","author":"\u00d8rbo","year":"2016","journal-title":"BJOG"},{"issue":"2","key":"2024102109252544800_djae023-B53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/ijgc-2022-004047","article-title":"ESGO\/ESHRE\/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"33","author":"Rodolakis","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2024102109252544800_djae023-B54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00404-021-06380-5","article-title":"Endometrial hyperplasia as a risk factor of endometrial cancer","volume":"306","author":"Nees","year":"2022","journal-title":"Arch Gynecol Obstetr"},{"issue":"4","key":"2024102109252544800_djae023-B55","doi-asserted-by":"crossref","first-page":"266.e1-12","DOI":"10.1016\/j.ajog.2012.08.011","article-title":"Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis","volume":"207","author":"Gallos","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"2024102109252544800_djae023-B56","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2021-002699","article-title":"Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: A systematic review and meta-analysis","volume":"31","author":"Chae-Kim","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"2024102109252544800_djae023-B57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejogrb.2022.04.019","article-title":"Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: a systematic review and meta-analysis","volume":"273","author":"De Rocco","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"12","key":"2024102109252544800_djae023-B58","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1136\/ijgc-2022-003882","article-title":"Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia","volume":"32","author":"Chen","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"2024102109252544800_djae023-B59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2017.07.120","article-title":"Effects of metformin on endometrial cancer: systematic review and meta-analysis","volume":"147","author":"Meireles","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2024102109252544800_djae023-B60","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ygyno.2020.02.008","article-title":"The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia\/endometrial intraepithelial neoplasia or endometrial cancer: little impact on response and low live-birth rates","volume":"157","author":"Acosta-Torres","year":"2020","journal-title":"Gynecol Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djae023\/57035310\/djae023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/5\/653\/59923722\/djae023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/5\/653\/59923722\/djae023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T09:25:56Z","timestamp":1729502756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/116\/5\/653\/7596640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djae023","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,2,1]]}}}